Akrevia launches with $30M in Series A financing
The company, with ARIAD and Intellia veterans at the helm, aims to develop CTLA4-targeting monoclonal antibody that mitigates the immune toxicity of Bristol's Yervoy.
The company, with ARIAD and Intellia veterans at the helm, aims to develop CTLA4-targeting monoclonal antibody that mitigates the immune toxicity of Bristol's Yervoy.
In addition to the funding, which was led by Accel, Eight Roads Ventures and F-Prime Capital Partners, the company announced it has opened a new office in Cambridge, Massachusetts.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Oak HC/FT and F-Prime Capital Partners led the Series A round for the California startup, while Maverick Ventures and Greylock Partners participated.
The company plans to use blockchain and other technologies to develop the genomic data marketplace, under a partnership with Veritas Genetics.